Two independent real-world studies add to the evidence that semaglutide — the drug in Ozempic and Wegovy — may affect more than metabolism. In one study, users had nearly 40% fewer asthma attacks and roughly 20% fewer COPD flare-ups. In another, a Swedish study of nearly 15,000 people with bipolar disorder found a 21% lower risk of psychiatric hospitalization among semaglutide users.
The two studies address different conditions, but they agree on a broader theme: semaglutide's effects may extend beyond weight loss and diabetes control. The respiratory findings come from a large real-world dataset, while the psychiatric findings come from a national cohort. Neither study establishes causation — both are observational, and researchers caution that unmeasured factors could play a role.
Together, these results hint at possible anti-inflammatory or neuroprotective actions for GLP-1 drugs, though the exact pathways are not yet defined. The studies also highlight the value of mining real-world health data to uncover unexpected benefits of existing medications, even as clinical trials remain the gold standard for confirmation.